Head and Neck Cancer Clinical Trial
Official title:
Training Swallowing Initiation During Expiration: Impact on Safety and Efficiency Following Treatment for Oropharyngeal Head and Neck Cancer
NCT number | NCT05278039 |
Other study ID # | R01CA262502 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | May 19, 2022 |
Est. completion date | July 1, 2026 |
Head and neck cancers have escalated to epidemic levels in the United States, and survivors are suffering from life-long, devastating swallowing disorders with limited therapeutic options. This clinical trial investigates a novel swallowing treatment that trains initiation of swallowing during the expiratory phase of respiration to improve swallowing safety and efficiency.
Status | Recruiting |
Enrollment | 88 |
Est. completion date | July 1, 2026 |
Est. primary completion date | July 1, 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Diagnosis of primary head and neck cancer - Three or more months post-completion of first-line cancer treatment - English speaking - Functional/corrected visual and hearing acuity - No current alcohol or other drug abuse - Without very severe (forced expiratory volume; FEV) 1 <30% predicted) stage Chronic Obstructive Pulmonary Disease (COPD) based on Pulmonary Function Testing (PFT) - No skin allergy to the medical-grade sensor adhesive - Tolerate wearing the sensor for at least 10 hours/day - Tolerate some liquid oral intake on a routine basis - Normal dexterity to self-administer liquids via teaspoon - Initiation of swallowing during inspiratory phase of respiration on =20% of swallows - Penetration Aspiration Scale (PAS) score =3 or impairment on at least one MBSImP OI score (laryngeal vestibular closure =1, tongue base retraction =2, or pharyngeal residue =2) on at least one swallow during lateral view of MBSS - A PAS score of =6 on at least one liquid consistency without the use of a compensatory strategy or swallow maneuver Exclusion Criteria: - Persistent or recurrent cancer at the time of enrollment - Known allergy to contrast materials or liquids used during the MBSS or training - Known allergy to sensor adhesive - Unable to demonstrate competency with the user-friendly technology - Diagnosis of neurological disorders - Indwelling tracheostomy tube - Nasogastric (NG) feeding tube - History of aspiration pneumonia within the past 12 months - Unable to self-administer liquid boluses - Unable to swallow some liquids without a maneuver - Likely or currently pregnant |
Country | Name | City | State |
---|---|---|---|
United States | Northwestern Memorial Hospital | Chicago | Illinois |
United States | Northwestern University | Evanston | Illinois |
Lead Sponsor | Collaborator |
---|---|
Northwestern University | Northwestern Memorial Hospital |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Change in M.D. Anderson Dysphagia Inventory (MDADI) scores | Evaluates the impact of dysphagia on the quality of life of patients with head and neck cancer | Change from baseline to 1-week post-treatment, 1-month post-treatment, and 3-months post treatment. Scores range from 20 to 100 and higher scores indicate worse outcome. | |
Primary | Change in frequency (%) of swallows initiated during expiration | Determines percent (frequency) of the target (expiratory phase) for each swallow. | Change from baseline to 1-week post-treatment and 2-4-6-8-10-12-weeks post-treatment. | |
Primary | Change in Penetration-Aspiration Scale scores | Measures presence, depth and reaction to penetration and aspiration. | Change from baseline to 1-week post-treatment, 1-month post-treatment, and 3-months post treatment. Scores range from 1-8 and higher scores indicate worse outcome. | |
Secondary | Change in Normalized Residue Ratio Scale scores | Quantifies pharyngeal space residue obtained in the lateral view during Modified Barium Swallow Study (MBSS) | Change from baseline to 1-week post-treatment, 1-month post-treatment, and 3-months post treatment. Scores range from 0 to 100% and higher scores indicate worse outcome. | |
Secondary | Change in Modified Barium Swallow Impairment Profile (MBSImP) scores | Measures physiologic swallowing impairment from observations of MBSS recordings | Change from baseline to 1-week post-treatment, 1-month post-treatment, and 3-months post treatment. Oral Total scores range from 0-22 and Pharyngeal Total scores range from 0-26 and higher values indicate worse outcome. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05808920 -
The RESCUE Study: Survival and Functional Outcomes Following Salvage Surgery for RESidual or reCurrent sqUamous cEll Carcinoma of the Head and Neck
|
||
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03997643 -
Preservation of Swallowing in Respected Oral Cavity Squamous Cell Carcinoma: Examining Radiation Volume Effects (PRESERVE): A Randomized Trial
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04700475 -
Effect of Low Level Laser Therapy on Prevention of Radiotherapy Induced Xerostomia in Cancer Patients.
|
N/A | |
Withdrawn |
NCT04058145 -
AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma
|
Phase 2 | |
Completed |
NCT02572869 -
Functional and Aesthetic Outcomes After Mandible Reconstruction With Fibula Osteomyocutaneous Free Flaps
|
||
Active, not recruiting |
NCT04474470 -
A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer
|
Phase 1/Phase 2 | |
Withdrawn |
NCT05073809 -
Photoacoustic Imaging of Head and Neck Tumours
|
||
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Active, not recruiting |
NCT03651570 -
Randomized Controlled Trial of a E-intervention to Help Patients Newly Diagnosed With Cancer Cope Better: Pilot Study
|
N/A | |
Recruiting |
NCT04930432 -
Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06016699 -
Immunological Function After Radiation With Either Proton or Photon Therapy
|
||
Terminated |
NCT03843554 -
Commensal Oral Microbiota in Head and Neck Cancer
|
N/A | |
Recruiting |
NCT05915572 -
Mulligan Technique on Shoulder Dysfunction
|
N/A | |
Completed |
NCT05897983 -
Tens and Rocabado Exercises on TMJ Dysfunction
|
N/A | |
Not yet recruiting |
NCT06289049 -
Heavy Strength Training in Head and Neck Cancer Survivors
|
Phase 2 | |
Withdrawn |
NCT05263648 -
Virtual Reality Software to Reduce Stress in Cancer Patients
|
N/A | |
Withdrawn |
NCT03238638 -
A Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy
|
Phase 2 |